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Hirschsprung disease is a congenital form of aganglionic megacolon that results from cristopathy. Hirschsprung
disease usually occurs as a sporadic disease, although it may be associated with several inherited conditions, such as
multiple endocrine neoplasia type 2. The rearranged during transfection (RET) proto-oncogene is the major
susceptibility gene for Hirschsprung disease, and germline mutations in RET have been reported in up to 50% of the
inherited forms of Hirschsprung disease and in 15–20% of sporadic cases of Hirschsprung disease. The prevalence of
Hirschsprung disease in multiple endocrine neoplasia type 2 cases was recently determined to be 7.5% and the co-
occurrence of Hirschsprung disease and multiple endocrine neoplasia type 2 has been reported in at least 22 families
so far. It was initially thought that Hirschsprung disease could be due to disturbances in apoptosis or due to a
tendency of the mutated RET receptor to be retained in the Golgi apparatus. Presently, there is strong evidence
favoring the hypothesis that specific inactivating haplotypes play a key role in the fetal development of congenital
megacolon/Hirschsprung disease. In the present study, we report the genetic findings in a novel family with multiple
endocrine neoplasia type 2: a specific RET haplotype was documented in patients with Hirschsprung disease
associated with medullary thyroid carcinoma, but it was absent in patients with only medullary thyroid carcinoma.
Despite the limited number of cases, the present data favor the hypothesis that specific haplotypes not linked to RET
germline mutations are the genetic causes of Hirschsprung disease.
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INTRODUCTION
We will briefly review Hirschsprung disease (HSCR), multi-
ple endocrine neoplasia type 2 (MEN2), and the co-segregation
of these conditions in the few families that have been studied to
date. In addition, we will discuss the existing hypotheses to
explain the finding of HSCR associated with MEN2.
HIRSCHSPRUNG DISEASE
HSCR (MIM #142623) is a congenital intestinal mal-
formation characterized by aganglionic megacolon in a
variable length of the intestine; both short- and long-
segment forms of the disease exist (1). The incidence of this
congenital megacolon is 1 per 5,000 newborns, although it
varies from 1.5 in Caucasians to 2.8 in Asians for each 10,000
newborns. HSCR is a neurocristopathy most frequently
found in its sporadic form (S-HSCR, ,70% of cases) which
is a non-Mendelian disease with low, sex-dependent
penetrance and variable clinical expression (1–3). Familial
forms of HSCR (F-HSCR) usually occur in association with
several inherited syndromes, such as MEN2 (4–13).
Recently, a Hirschsprung disease consortium verified that
germline mutations in the RET proto-oncogene have been
reported in up to 50% of patients with F-HSCR and in 15-
20% of patients with S-HSCR (2). RET is the major
susceptibility gene for HSCR, although up to 10 genes and
five different loci have been associated with HSCR devel-
opment (1,2). The short-segment form of the condition is
more frequent (80%) than the long-segment form [20%], and
recently developed surgical approaches for both forms have
a high chance of success, markedly decreasing the mortality
and morbidity rates of this condition (2,14-17).
Diagnosis of HSCR is usually confirmed by rectal biopsy
in newborns with intestinal obstructions with the following
findings: failure of meconium delivery in the first 2 days of
life, abdominal distention that is alleviated with rectal
stimulus and enema, vomiting, and neonatal enterocolitis.
The shorter the aganglionic segment, the later the signals
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and symptoms develop and consequently the more delayed
the diagnosis of HSCR (2,3,16).
MEN2
MEN2 (MIM #171400) is an inherited syndrome caused
by germline mutations in the RET proto-oncogene, which
encodes the RET receptor tyrosine kinase. Three neuroen-
docrine neoplasias are usually present: medullary thyroid
carcinoma (MTC), pheochromocytoma (PHEO), and pri-
mary hyperparathyroidism. Two other subtypes of MEN2
are familial MTC (FMTC; MTC only) and MEN2B (MTC;
PHEO, and ganglioneuromas) (7,13,18,19).
HIRSCHSPRUNG DISEASE CO-OCCURRING WITH
MEN2
In MEN2A, MTC and PHEO are the most prevalent
causes of morbidity and mortality, although HSCR is also an
infrequent but potentially life-threatening MEN2 phenotype
(2,18,19). In contrast, in sporadic MTC there are no other
associated neuroendocrine tumors and HSCR has not been
reported to date (20,21).
Recently, an international consortium on RET exon 10
studied 340 affected subjects from 103 MEN2 families and
assessed the risk profiles and penetrance estimations of
MEN2 patients who were diagnosed with germline RET
mutations in exon 10. In this study, 267 MEN2 patients were
investigated for HSCR disease and an overall penetrance of
7.5% was observed (22). Of note, carriers of germline RET
mutations in codon 620 were more prone to HSCR (13%),
especially those with C620R or C620G substitutions (14–
33%), although RET 618 and 609 codon mutation carriers
may also present with HSCR (22).
Present hypotheses
The co-occurrence of the HSCR and MEN2 (HSCR/
MEN2) phenotypes raises an apparent paradox because
MTC is caused by activation of cellular growth signaling of
the RET tyrosine kinase receptor, while HSCR is largely
associated with disruption of this pathway because of
inactivating RET mutations (1). Initially it was thought that
disturbed mechanisms of apoptosis might lead to HSCR
(23). Several investigations have examined this topic (24–
33).
At present, there are two main hypotheses to explain the
occurrence of HSCR/MTC within MEN2 families. The first
states that MEN2-associated RET mutations, mostly in exon
10, may play a dual activating and inactivating role in the
RET tyrosine kinase molecular pathway, leading to con-
stitutive activation of the RET receptor. The mutated RET
receptor would present a tissue-specific tendency to be
retained in the Golgi apparatus, leading to a reduced
number of RET membrane receptors in the intestine and,
therefore, decreased intracellular tyrosine signaling (24).
The second hypothesis is that the RET-activating muta-
tions play either no role, or only a minor role, in HSCR
development (2). In this scenario, low-penetrant and dose-
dependent, specific predisposition to RET haplotypes may
lead to a reduction in RET tyrosine receptor activation
during embryonic life, leading to neuronal and intestinal
cell disturbances and, finally, HSCR. Of note, both protec-
tive and predisposing haplotypes to HSCR have been
described (2). There is strong evidence favoring the
hypothesis that specific haplotypes play a key role in the
fetal development of congenital megacolon (2,32). Recent
data suggest that mutations in RET ligand genes may be
responsible for a small proportion of HSCR cases (33).
As previously mentioned, the prevalence of HSCR in
MEN2 cases has been recently determined to be 7.5% (22).
Borrego et al. (10) reported that 13 HSCR/MEN2 families
had been described up to 1998. At present, up to 22 HSCR/
MEN2 families have been reported, although the number of
families that have been genetically investigated is relatively
limited (2,4,12). S-HSCR or F-HSCR cases have been
extensively studied clinically; however, further genetic
haplotype analyses may contribute to a better understand-
ing of the molecular causes of familial HSCR associated
with MEN2.
LOCAL EXPERIENCE
Although a limited number of affected familial cases from
this new FMTC/MEN2 genealogy could be studied, data
from patients with either MTC alone or HSCR associated
with MTC/MEN2 were available to be analyzed.
A novel HSCR/FMTC family
Herein we report the results of the genotyping analysis of
a novel HSCR/FMTC family that carries the germline
c.1858T.C (p.C620R) RET activating mutation in exon 10.
The patients come from a rural area of northeast Brazil and
have been diagnosed, treated and followed for several years
at the University of Sa˜o Paulo School of Medicine, Academic
Hospital (Hospital das Clı´nicas, southeast Brazil) (Figure 1).
Early recognition of HSCR in the studied cases was
achieved with routine investigations for HSCR (15,16). The
recommended surgical approach for HSCR was used,
allowing the affected patients in the study to survive longer
(14,17). The two patients with HSCR/MEN2 who were
operated on in our hospital had the long-segment form of
HSCR. No renal/urinary disturbances were observed in our
cases, consistent with the findings from the HSCR mouse
model (34). Several RET gene mutation carriers from this
family underwent preventive or curative total thyroidect-
omy. We have recently reported partial phenotypic data
obtained from this large FMTC/MEN2 family (22).
Visit to the area
During a recent visit to the area where the family
originally lived and where most patients still live
(2,500 km from Sa˜o Paulo), written informed consent was
obtained and blood samples for DNA analysis were
collected from several at-risk family members. The research-
ers were informed that the family had experienced three
neonatal deaths of babies who were operated on for
congenital megacolon at a local hospital, but not in time to
save their lives. The institutional ethics committee has
approved this research project.
Haplotype investigation
To verify if an additional and inactivating RET mutation
was present in the C620R-mutated HSCR patients in this
family, the 21 exons of the RET proto-oncogene were
analyzed by polymerase chain reaction amplification and
bidirectional sequencing, as previously reported (35). No
germline RET mutation other than C620R was observed. We
also investigated whether RET single nucleotide poly-
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morphisms (SNPs) or specific haplotypes were involved.
Haplotypes were estimated using the EHPlus and Hapi
software programs (http://linkage.rockefeller.edu). Geno-
typing data on 16 RET intragenic SNPs were as follows:
rs2505533, novel SNP-1, rs2505532, rs72781232, rs2505531,
rs2565206, rs1800858, rs1864404, novel SNP-2, rs1800860,
rs3026750, rs34827976, rs1799939, rs1800861, rs1800862, and
rs1800863 (Table 1).
Initially, the haplotype CTCGTGGTGAdel (rs2505533,
IVS1-126, rs2505532, rs72781232, rs2505531, rs2565206,
rs1800858, rs1864404, rs1800860, rs3026750 and rs34827976)
was documented in all of the studied C620R-mutated
relatives in the present family, indicating that this haplotype
is linked to the RET mutation.
Because not all of family members with the RET mutation
had developed HSCR, the emerging hypothesis was that
HSCR disease maybe associated with genetic variants in the
remaining chromosome region. In accordance with this
assumption, the MEN2-affected relatives who did not have
HSCR were believed to have inherited the CATACTGTAAdel
haplotype, while the HSCR/MEN2 patients had inherited a
different haplotype, TTCGTTAAAGC (Figure 1).
The RET gene region that includes the observed haplo-
types in this new MEN2 family, especially the combination
of the SNPs from rs2505533 to rs2565206 in linkage
disequilibrium with SNPs rs1800858 and rs1800861, has
been previously implicated in the development of both
sporadic and familial forms of HSCR (1,2). Furthermore,
analysis of four additional members of this family with the
C620R mutation (three cases without and one with HSCR)
strengthened the proposal that this RET gene region is
involved in the development of HSCR (n = 9; p= 0.012;
Fisher exact test). It is worth noting that only HSCR patients
were homozygous for the four SNPs located in the
implicated region: rs2565206, rs2505532, rs72781232, and
rs2505531 (Figure 1). Concordantly, RET exon 2 A45A SNP
has been found in the homozygous state in cases with HSCR
Figure 1 - Identification of different haplotypes, including the rs2505533 and rs34827976 SNPs, in relatives with MTC/HSCR or MTC
alone (non-HSCR) who carry the C620R RET mutation. The observed haplotype in the HSCR/MTC patients (red) contains the region
previously recognized as related to the sporadic and familial forms of HSCR (1,2). Four SNPs within this region are only homozygous
(aa) in patients with HSCR.
Table 1 - Sixteen RET intragenic SNPs that were
genotyped in patients with MTC alone or HSCR/MTC from
a newly reported FMTC/MEN2 family.
SNP* Location DNA Protein
rs2505533 Intron 1 c.74-1454T.C /
Novel SNP c.74-1379T.A /
rs2505532 c.74-1362C.T /
rs72781232 c.74-1329G.A /
rs2505531 c.74-1290T.C /
rs2565206 c.74-126G.T /
rs1800858 Exon 2 c.135G.A p.A45A
rs1864404 Intron 5 c.1064-89A.T /
Novel SNP Intron 7 c.1522+58C.A /
rs1800860 Exon 7 c.1296A.G p.A432A
rs3026750 Intron 8 c.1648+84G.A /
rs34827976 c.1648+88delC /
rs1799939 Exon 11 c.2071G.A p.G691S
rs1800861 Exon 13 c.2307T.A p.L769L
rs1800862 Exon 14 c.2508C.T p.S836S
rs1800863 Exon 15 c.2712C.G p.S904S
*Please see http://www.ncbi.nlm.nih.gov/snp.
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only, whereas MEN2 patients and healthy controls are
frequently heterozygous for this SNP (2,31).
In summary, we have presented new evidence supporting
the role of a RET haplotype, which is not linked to the C620R
mutation, in the development of HSCR in a newly reported
FMTC/MEN2 family. Our findings support the hypothesis
that the occurrence of HSCR in MEN2 families is not caused
by any additional RET-inactivating mutation. Rather, it is
most likely due to the combination of low-penetrance RET
SNPs in the previously recognized HSCR-risk region between
SNPs 2505533 and 2565206. The TTCGTTAAAGC RET
haplotype may be helpful as a genetic marker for HSCR,
which would ultimately translate into improved medical care
for these patients.
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